Article successfully added.

CyFlow™ CD30 Purified

CyFlow™ CD30 Purified
Alternative Name: D1S166E , Ki-1, TNFRSF8
Antibody: Yes
Antigen: CD30
Application: Flow cytometry, Immunohistochemistry
Clonality: monoclonal
Clone: Ber-H8
Field of Interest: Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG1
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CL576329

For Research Use Only

HLDA Workshop HLDA III—WS Code A171 HLDA IV—WS Code A105 HLDA V—WS Code A042 Concentration... more
CyFlow™ CD30 Purified
HLDA WorkshopHLDA III—WS Code A171 HLDA IV—WS Code A105 HLDA V—WS Code A042
Concentration Unitmg/mL
Quantity0.1 mg
Volume0.1 mL
ImmunogenNot available
Background InformationCD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 immune response.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki‑1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1; 85(1):41640. < PMID: 7803786 > | Franke AC, Jung D, Ellis TM: Characterization of the CD30L binding domain on the human CD30 molecule using anti‑CD30 antibodies. Hybridoma. 2000 Feb; 19(1):43‑8. < PMID: 10768840 > | Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti‑CD30 antibody treatment in vitro. J Immunol. 2004 Feb 15; 172(4):2186‑93. < PMID: 14764685 > | Berro AI, Perry GA, Agrawal DK: Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1; 173(3):2174‑83. < PMID: 15265955 > | Aalberse JA, Kapitein B, de Roock S, Klein MR, de Jager W, van der Zee R, Hoekstra MO, van Wijk F, Prakken BJ: Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60). PLoS One. 2011; 6(9):e24119. < PMID: 21931651 >